## 505860785 01/13/2020

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5907722

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
ANDREW GEALL	03/12/2013
KATRIN RAMSAUER	03/21/2013
GILLIS OTTEN	03/12/2013
CHRISTIAN MANDL	03/11/2013

#### **RECEIVING PARTY DATA**

Name:	NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Street Address:	4560 HORTON STREET
City:	EMERYVILLE
State/Country:	CALIFORNIA
Postal Code:	94608

#### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16740924

### **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: US cipkop@gsk.com

Correspondent Name: GLAXOSMITHKLINE GLOBAL PATENTS UP4110

Address Line 1: 1250 SOUTH COLLEGEVILLE ROAD
Address Line 4: COLLEGEVILLE, PENNSYLVANIA 19426

ATTORNEY DOCKET NUMBER:	VN54242D1C1 US
NAME OF SUBMITTER:	ERIC J. KRON
SIGNATURE:	/Eric J. Kron/
DATE SIGNED:	01/13/2020

### **Total Attachments: 8**

source=VN54242D1C1\_US\_Assignment\_Chain#page1.tif source=VN54242D1C1\_US\_Assignment\_Chain#page2.tif source=VN54242D1C1\_US\_Assignment\_Chain#page3.tif source=VN54242D1C1\_US\_Assignment\_Chain#page4.tif

PATENT 505860785 REEL: 051496 FRAME: 0287

source=VN54242D1C1\_US\_Assignment\_Chain#page5.tif
source=VN54242D1C1\_US\_Assignment\_Chain#page6.tif
source=VN54242D1C1\_US\_Assignment\_Chain#page7.tif
source=VN54242D1C1\_US\_Assignment\_Chain#page8.tif

PATENT REEL: 051496 FRAME: 0288

#### ASSIGNMENT

This Assignment Agreement is entered into by and between Andrew Geall, a citizen of Great Britain, Katrin Ramsauer, a citizen of Austria, Gillis Otten, a citizen of the United States of America, and Christian Mandl, a citizen of Austria (hereinafter "Inventor(s)"), and NOVARTIS VACCINES AND DIAGNOSTICS, INC., 4560 Horton Street, Emeryville, California 94608, a company organized under the laws of the State of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS VACCINES AND DIAGNOSTICS, INC., is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS VACCINES AND DIAGNOSTICS, INC., and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

# DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS [Patent Case PAT054242-WO-PCT]

and filed in the United States Patent and Traden	nark Office on	, 2013 and
accorded Application Number		International Application
on July 6, 2011 and accorded International Pater	nt Application Number	PCT/US2011/043104;
and/or filed in the United States Patent and Trac	lemark Office on	and
accorded Application Number ;		

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other

1

applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;
- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates,

and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the State of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this	12.	day of	Narch	_, 2013.
		Nec		L.S.
Andrew Geall				
Witness				
Executed this		_day of		_, 2013.
Katrin Ramsaue	····			L.S.
Naum Kamsauc				
Witness				

Executed this 10th day of 14mh	_ , 2013. L.S.
Gillis Otten  Witness	E.O.
Executed this // day of // Rev. L Christian Mandl Witness	
Executed this day of  NOVARTIS VACCINES AND DIAGNOS	
BY	L.S.
Witness	<u></u>

## ASSIGNMENT

This Assignment Agreement is entered into by and between Andrew Geall, a citizen of Great Britain, Katrin Ramsauer, a citizen of Austria, Gillis Otten, a citizen of the United States of America, and Christian Mandl, a citizen of Austria (hereinafter "Inventor(s)"), and NOVARTIS VACCINES AND DIAGNOSTICS, INC., 4560 Horton Street, Emeryville, California 94608, a company organized under the laws of the State of Delaware.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS VACCINES AND DIAGNOSTICS, INC., is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS VACCINES AND DIAGNOSTICS, INC., and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to

(1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

# DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS [Patent Case PAT054242-WO-PCT]

and filed in the United States Patent and Traden		
accorded Application Number	<del>and/or</del> filed as a PCT International	Application
on July 6, 2011 and accorded International Pater	nt Application Number <u>PCT/US2011</u>	<u>/043104;</u>
and/or filed in the United States Patent and Trad	lemark Office on	<del>and</del>
accorded Application Number;		

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other

1

applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);
- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals:
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;
- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates,

and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of the State of Delaware.

This Assignment is effective as from the earliest priority date as stated above.

Executed this	day of	, 2013.
		L.S.
Andrew Geall		AND THE PROPERTY OF THE PROPER
Witness		
Executed this	1 <sup>54</sup> day of <u>NAV2.14</u>	, 2013.
Valxie (	Rameray	L.S.
Katrin Dameans	P .	
Mud	MAL	
Witness	<u> </u>	

Executed this	day of	, 2013.
		L.S.
Gillis Otten		
Witness		
Executed this	day of	, 2013.
		L.S.
Christian Mandl		
Witness		
AA 1111C22		
Executed this	1 day of	<u>,</u> 2013.
NOVARTIS VAC	CCINES AND DIAG	NOSTICS, INC.
BY_//\}	***************************************	L.S.
Witness Witness	1	L.S.
Witness	Dien S	rio-